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For healthcare providers, patient safety has always been a
concern and a priority. The 19991nstitute of Medicine report
took a critical look at safety in the American hospital system
and found it lacking. Since then, numerous organizations and
medical groups have united around a common set of principles
summarized here:
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A safety conscious environment - a nonpunitive culture
that encourages reporting healthcare errors, focusing on
system failures rather than individual culpability
Data analysis - comprehensive review of information
reported to ensure that we reduce the risk of reported
events recurring
Confidentiality - protection for patients, healthcare
professionals and healthcare organizations is essential for
any reporting system
Information sharing - reporting systems should exchange
information and foster collaboration in the search for
solutions
Legal status of reported information - the lack of federal
immunity for information submitted will deter effective
reporting mechanisms.

The debate now in Congress is whether to create federal
legislation mandating reporting of medical errors versus a
focus on reducing healthcare errors at the local level.
Secretary of Health and Human Services, Tommy Thompson,
has created a Patient Safety Task Force to address medical
errors.
The medical staff endorses this effort, and we at LVH have
taken a major step forward in utilizing available technology to
reduce medical errors. It is called computer assisted physician
order entry (CAPOE), capably led by Dr. Don Levick, chair of
the LVPHO Information Services Committee. As reported in

Valley Preferred News (6/01}, this group has also "looked at a
(Continued on Page 2)
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variety of electronic applications, including office management
software, prescription writing modules and health information
sites."
How about ChanneiHealth, a secured webstte accessed via
the Internet? It features patient information access and clinical
reference material- now available in your office through the
web- access limned to this planet. (Call LVH Information
Services at (610) 402-8303.)
As Rich Boorse is fond of saying, "Buckle your seat belts,
folks." We live in exciting times. Medical care is changing and
we must change with it to provide continued quality care for
our patients and our community. Their trust is in the balance.

"My responsibility is to get my 25 guys playing for the name on
the front of their uniform and not on the back."
-Tommy Lasorda
Coach, LA Dodgers

Malpractice in Pennsylvania
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Carol Rose (a practicing anesthesiologist from Pittsburgh and
current president of Pennsylvania Medical Society) put it, "I
believe and I belong." Expect the Pennsylvania Trial Lawyers
Association to fight all tort reform efforts with self-righteous
indignation. They continue to defend the costly present tort
system as the protector of public safety, but there's one major
flaw in their argument The present tort system is simply not
working! Think about it! The problem is not getting better; it's
getting worse. The public deserves a different and better
system of addressing medical errors, one that does not siphon
off precious medical resources to subsidize our legal brethren.

Newswire item: Pottstown Memorial Medical Center Is
Having Difficulty Securing Medical Malpractice Liability
Excess Coverage.
John Buckley, president and CEO of the western Montgomery
County hospital, said that Pottstown Memorial had a 78 percent
increase in medical liability premiums for fiscal 2002, that the
hospital's institutional excess coverage-which insures the
hospital against awards in excess of$1.2 million-hasn't been
renewed, and that he can't find any insurers willing to provide the
coverage because of higher-than-average jury awards in
malpractice cases in southeastern Pa.,reported the Business
Journal. (Philadelphia Business Journal, July 9, 2001)

First the good news Newswire item: The Pa. Senate unanimously passed a CAT
Fund Reform Bill.
SB 556, sponsored by Sen. Edwin Holl (R-Montgomery), would
transfer responsibility for the state's Medical Professional
Liability Catastrophe Loss Fund (CAT Fund) to an independent
authority with the power to issue bonds to cover liabilities as
the CAT fund is phased out over six years, placing all medical
liability coverage under private insurance. The bill now goes to
the House, where it is expected to be referred to the House
Insurance Committee. The House version of the bill (HB 1802}
is derived from the joint agreement on the CAT Fund's phaseout between the Pennsylvania Medical Society and the
Hospital & Healthsystem Association of Pennsylvania.
(Pennsylvania Medical Society, June 19, 2001)
This is clearly a start. Resolution of the lingering CAT Fund
problem, along with limitations on frivolous lawsuits, is very
encouraging. We should thank our state senators for their
support in making this happen.
Then, there's the bad news We still have a long way to go, and malpractice premiums in
this Commonwealth are still exceedingly high (40 to 70%
higher than in surrounding states}. Get in this game. As Dr.

"In basketball, you can be the greatest player in the world and
Jose evety game, because a team will always beat an
individual. •
-Bill Walton, professional basketball player
Graduate of UCLA system

HCFA is Dead (just when I was getting used to it), long live
CMS (I guess).
Newswire item: The Health Care Financing Administration
(HCFA) has been renamed as the Centers for Medicare
and Medicaid Services (CMS).
The Bush administration announced the name change of the
agency that runs Medicare and Medicaid in the hope of
repairing its image as a bureaucratic behemoth, while
Secretary of Health and Human Services Tommy Thompson
said the change symbolized his commitment to improving the
agency's services to beneficiaries, doctors, hospitals and other
health care providers, reported the New York Times.
Thompson announced that CMS will be reorganized into three
divisions: the Center for Beneficiary Choices, which will
provide information to Medicare patients in private health
(Continued on Page 3)
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, (Continued from Page 2)
plans; the Center for Medicare Management, which will run the
traditional fee-for-service version of the insurance program;
and the Center for Medicaid and State Operations, which will
handle Medicaid and the State Children's Health Insurance
Program, the Washington Post noted. (New York Times, June
15,2001)
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News from Central Scheduling

"To be a champion, you have to believe in yourself when
nobody else will. •
- Sugar Ray Robinson

On Monday, July 2, Central Scheduling in the Diagnostic Care
Center at Cedar Crest &1-78 began scheduling tests and
procedures performed in the hospital Radiology Departments
at Cedar Crest &1-78 and 171h &Chew (Ultrasound, CT Scans,
and FLUORO). These are in addition to those tests in Preadmission Testing, Non-invasive Cardiology, NEURO, PULM,
Nuclear Medicine and the Sleep Disorder Center currently
being scheduled by the Central Scheduling Department.
lnterventional Radiology (arteriograms, etc.) will continue to be
scheduled by the Radiology Department at (61 0) 402-8080
until later this fall.

Professional Attire- As healthcare professionals in a premier
academic community hospital, we should project an image with
our dress that indicates we take our mission seriously. Overly
casual attire (usually on weekends) may be inappropriate in
some patient care settings. We respectfully ask the medical
staff to use their good judgment in this regard.

Physician offices that are scheduling patients for radiology
procedures are reminded that there is still a separate phone
number to schedule tests at Lehigh Valley Diagnostic Imaging
(LVDI). If LVDI cannot accommodate the patient in a timely
manner or due to insurance plans, the exam may be
scheduled at 17th &Chew or Cedar Crest &1-78 (based on the
urgency of the study).

"For the great majority of mankind are satisfied with
appearance, as though they were realities and are often more
influenced by the
things that seem than by those that are."
- Niccolo Machiavelli

"Time management is an unfamiliar concept to most
physicians. In medical school and during residency,
physicians are never taught time management skills. As a
result, there is tremendous variability in the efficiency of
physicians. Almost all physicians can benefit from gaining
better time management skills ... my research had revealed that
all physicians have individualized patterns of inefficient and
efficient use of time. Once practitioners recognize their own
patterns, they can make major changes in how they utilize their
time."
-Marshall Zaslove, MD
Psychiatrist, author and productivity consultant

Beginning with this issue, a new feature - "Spotlight on ... "
-- will be included in Medical Staff Progress Notes. Every
month, this new feature will highlight a member of the Medical
Staff. This month's feature will include a Spotlight on John E.
Castaldo, MD (see article on Page 6).

Edward M. Mullin, Jr., MD
President, Medical Staff

Depending on the insurance plan that a patient has, most of
the procedures performed in Radiology require a referral and
an authorization number from the managed care company. In
addition, all tests are required to have a written order
(prescription) which includes appropriate signs and symptoms
as a reason for the test. In order to facilitate the patient's
experience when they arrive at the hospital, the scheduling
clerk will remind the office staff or the patient when the test or
procedure is scheduled, that the above is required. In order to
streamline the process from physician offices and decrease
phone calls back and forth, please communicate the
prescription and the referral and/or authorization numbers via
phone or fax to Central Scheduling prior to the scheduled test.
Patients who arrive without a referral, authorization, and/or
prescription, will unfortunately have to be rescheduled. In an
effort to avoid this from occurring, a scheduling clerk will call
the physician's office 48 hours in advance to secure any
necessary information that is still missing.
The number for Central Scheduling is (610) 402-TEST (8378).
The fax number is (610) 402-8708. For physician office
convenience, Central Scheduling is open Monday through
Friday from 7 a.m. to 7 p.m.
If you have any questions, comments or concerns, please
contact Lisa Coleman, Director of Support Services, at (610)
402-8066, or Mark Holtz, Vice President of Operations, at
(484) 884-4710.
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Required Ethics Education
The FDA will be requiring research ethics education in the near
future for all investigators conducting studies or submitting new
protocols. Listed below is a website that you may ~ish to visit
and get a headstart on this requirement by completmg the
training. The IRB Board members have already done this.
Those who have said it "wasn't that bad," "was actually
interesting," and "was fun."
If you do choose to complete the training, please forward your
completed certificates (you print them out yourseln to
Bernadette Glenn at Health Studies Research, 17th &Chew,
Suite #6-T-38. All investigators will eventually need to have
documentation on file in the IRB Office.
The following is the OHRP web site:
http://ohrp.osophs.dhhs.gov/
When arriving at the website, click on:
1. Educational Materials
2. Then, Tutorials "Training Modules for Assurances"
3. Individual must login to begin
There are three tutorials:
1. Federal Regulations & Institutional Responsibilities
2. Investigator Responsibilities & Informed Consent
3. Human Protections Program Administration & IRB
Responsibilities
If you have any questions regarding this issue, please contact
Bernadette Glenn at (610) 402-2529.

Coding Tip of the Month
When a patient is admitted with a lower extremity
ulcer and also carries a diagnosis of Diabetes and
Peripheral Vascular Disease, the coder looks for
documentation in the record that would link (cause
and effect) these.conditions. To know this
information helps to assign accurate DRGs and also .
assures appropriate Hospital reimbursement.

News from CAPOE Central
We have been live with CAPOE for approximately one month.
Overall, it has gone very well. I would like to thank the Medical
Staff for their patience with the new system. The majority of
the feedback on the TTU has been positive -- it appears that
most physicians appreciate being able to view Vital Signs, I
and O's, labs and medication administration all on one screen
(the Viewer).
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The Trauma Team (attendings and PA's) has shown incredible
patience and commitment toward making CAPOE work. The
PA's especially have been great to work with and have
provided invaluable feedback. The CAPOE team has already
made changes to the user interface based on their co~~ents.
The Pharmacy and Nursing staffs have had to learn s1gmficant
new work processes despite being understaffed. They have
done remarkably well, and I would also like to thank them and
acknowledge their efforts.
Several questions have come up regarding use of the system.
We are trying to respond to these issues in various venues,
including here in Medical Staff Progress Notes. Help is
available by calling the CAPOE Hotline at (610) 402-8303,
option #9. There is on-screen help accessible through the
"HELP" menu at the top of the Lastword screen. Choose
"CAPOE HELP," and you will be taken to a web page where
you can access on-line versions of the Lastwo~ and.CAPOE
manuals, a section on "Frequently Asked Questions, and an
index of "Tips and Tricks."
Several physicians have commented that the "Viewer" is
difficult to read, especially on the handheld devices. The
problem is that the size of the print (font) on the viewer is too
small or difficult to see. However, you can change the
typeface and size in the Viewer. When in the Viewer, go to the
VIEW menu at the top of the window. There are choices to
increase the font size (BIGGER FONT), which will
incrementally increase by the font size; and CHOOSE FONT,
which allows you to choose the font and the size. NOTE: the
changes are specific for each device or computer, and do not
stay with the user.
Physicians have also asked to be able to print their census
the same way as before, sorted by bed number and with th~
age and diagnosis. This can be easily done. From the Mam
Physician Base Screen, type "GCN" in the command field (the
open field at the bottom of the screen). This will brin~ up your
group census. Click on the PRINT CENSUS bu~on ~n the
lower right hand comer, and the census sheet Will pnnt out to
the printer assigned to that computer.
We will continue to respond to the questions and concerns of
the Medical Staff and other users. Everyone is committed to
making this a success. Please contact me if you would like
more information or have specific concerns.
Don Levick, MD, MBA
(484) 884-4593
(610) 402-5100 7481 (pager)
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INBOX Alerts & Reminders •• You Have
Orders to Sign

Click on the Review Selected Order Detail button to review
individual order details.

The INBOX- Alerts & Reminders portion of the Physician
Base screen in Lastword serves as a reminder to sign orders.

Click on the Review Audit button to review an Order Audit
Trail (i.e., the date/time an order was entered into the system).
All orders are selected by default, and can be unselected by
clicking on the appropriate check boxes located to the left of
each order. Click the Sign Selected Orders button to sign the
orders you selected. The orders are now signed in the system
just as you would have initialed written orders.
The INBOX- Alerts &Reminders feature also provides alerts
for abnormal lab results, new ancillary results, for whom you
are offering coverage, and the physician(s) covering for you.
To learn more about these features, please take a moment
and review the on-line documentation for Lastword Version
4.1.7. Both the CAPOE and Non-CAPOE Physician User
Guides can be found on the LVHHN Intranet under the
Resources heading Lastword for Physicians.

Figure 1 - Physician Base Screen in Lastword showing
INBOX location

If you wish to obtain a paper copy of one of these documents,
please contact Lynn Corcoran-Stamm at (610) 402-7053, or
Carolyn K. Suess, RN, at (610) 402-7052.

In an instance where a PA or medical student enters an order
for a patient, or the attending physician calls in a telephone
order, the CAPOE system requires the electronic signature of
the attending physician for the order. The You Have Orders to
Sign reminder appears in the INBOX window when these types
of orders generate.

Phys·ician Parking Duri.ng the
·
Allentown Fair .

To access unsigned orders, click on this alert located in the
INBOX window, then click on the Select button located at the
bottom of the window. The Sign Orders window opens (see
Figure 2). A list of outstanding orders is selected for you to
sign.
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It's that time of the year again . . .
time to begin preparation for the
Great Allentown Fair. As in past
years, parking changes will be made
for physicians and housestaff at fih
& Chew. Beginning Tuesday, .
August 14, through Monday, ·
September 10, parking for physicians
and housestaffwill be·reassigfled to
Lot #4 .(No.rth:west Street} and Lot·
#5 (Gordon Street). PhysiciaD and
housestaff photo IPs will be
programmed to access these areas
during this period.
lfyou have any questions regarding
this issue, please contact louis
Geczi in SecuritY at(610) 402~2986.

,.
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John E. Castaldo, MD

Born in Mount Vernon, N.Y., Dr. Castaldo is a graduate of
Dartmouth College, Hanover, N.H., where he received a
Bachelor of Arts degree. He received his medical degree from
Dartmouth Medical School, and completed his internship
followed by a three-year residency at Dartmouth-Hitchcock
Medical Center. Following his residency, Dr. Castaldo joined
the Lehigh Valley Hospital Medical Staff in 1983. He is a
member of the Department of Medicine, Division of Neurology,
and is in practice with Lehigh Neurology. He was recently
named Chief of the Division of Neurology.
As a seasoned member of the hospital's Medical Staff, Dr.
Castaldo held the prestigious position of Medical Staff
President from 1995 to 1996. He also served as a member of
the hospital's Board of Trustees from 1993 to 1998. Dr.
Castaldo has also served as a member on numerous
committees including: Ethics Committee, Resident Review
Committee, Institutional Review Board, Medical Executive
Committee, Performance Improvement Council, Clinical Case
Review Committee, Hospital-Wide Quality Assurance
Committee, Functional Planning Steering Committee, Hospital
Staff Development Advisory Committee, and the Nomination
Committee for the Board of Trustees.
In 1997, Dr. Castaldo was awarded the Hahnemann School of
Medicine - Dean's Special Award for Excellence in Clinical
Teaching. In 1999, he was appointed Professor of Clinical
Medicine at Penn State University/Milton S. Hershey Medical
Center.
As the Director of Neuroscience Research, Dr. Castaldo has
been extensively involved in a number of research studies
including LOVAR - Lowering of Vascular Atherosclerotic Risk
Trial (see article on Page 7). In addition, he has co-authored
numerous journal articles and book chapters.
Dr. Castaldo and his wife, Nancy, have three sons- David,
Mark and Nick. In his spare time, he enjoys bike riding,
woodworking, and playing guitar.
In conclusion, Dr. Castaldo has the following "words of
wisdom" to offer to the Medical Staff:

1. Do the Right Thing, which is often not easy, expedient or
inexpensive.
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2. Listen more; speak less - so you'll know the right thing
when you see it.
3. Make time for relationships every day. Nurture and
cherish them.
4. Aspire to achieving excellence if only in small incremental
steps.
5.

Bring more to the table than you take away- and your
table will be always bountiful.

6.

Be humble. Respect those more experienced than you.

7. Fix things and people you find broken as much as is
possible.
8. Accept and embrace diversity in all its forms.
9. Remember that compromise is a pillar of collaboration; not
a fall back position.

10. Preserve and inspire enthusiasm for the greater good.

2001 United Way Campaign
Annually, nearly 1,300 Lehigh Valley children and
youth require tax-support services totaling $29.2
million- an average of $22,500 per child. However,
with help from you .and others like you, the average
cost for a child served by the Boys and .Girls Clubs is
$300; the Learning Club : $1, 130; and after-school' .
programs -.$510.
Please plan to Join your colleagues in· partiqipating in
this.year's 2001 LVHHNUnited Way Campaign,
which wiJI kick-off on August 16. Thi.s year's goal is
a lofty one: to raise·$257;783 and to increase ·,
participation by 25% to 1,611· donors.
·
Physicians and staff will receive a. personalized
pledge and designation form early in Septe111ber. :It
is hoped that you will become part of the LVHHN
United Way Team this year with your participation.
Remember TEAM =Together· Everyone Achieves.
More.
Watch for more information in next month's issue of
Medical Staff Progress Notes. If you have arl'y ·
questions, please contact one of the campaign cochairs -'·Betty Anton, Director of VOlunteer Services,
at(610) 402-8897, or Don Hougendobler, Director of
Safety/LVH-M Housekeeping, at (484) 884-2293 ..
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KePRO Project: Admission vs.
Observation Stay
KePRO, the Peer Review Organization for Pennsylvania, is
responsible for monitoring the quality care of Medicare
beneficiaries. KePRO initiated a project evaluating the
appropriateness of hospital one-day stays with a focused
review on specified DRGs. The review was primarily
educational, but also enables KePRO to identify causes of
payment errors. No approval or denial determinations were
made. This review provides an opportunity to make necessary
changes prior to having a monetary effect.
Among the short stay population, KePRO indicated that there
was a lack of severity of illness and the provision of few acute
care services. The following summarizes their findings based
on cases reviewed for both Lehigh Valley Hospital and Lehigh
Valley Hospital-Muhlenberg:
DRG
DRG 243 Medical Back
Problems
DRG 065 Oysequilibrium
DRG 015 Trans Ischemic
Attack
DRG 320 Urinary Tract
Infections
Overall

% of Cases Not Meeting
Admission Criteria
67%
91%
84%
76%
83%

A LVHHN physician advisor conducted a similar internal review
for DRG 143: Chest Pain, and found 79% of the cases did not
meet criteria.
Based on these results, KePRO suggests that patients failing
to meet admission criteria should have been treated in an
outpatient setting or observation. Observation may occur
anywhere in the hospital, i.e., in the Emergency Department,
patient floor, any care unit appropriate to the services being
rendered, where the need is clearly documented. To avoid
confusion, KePRO recommends that physicians use the
language "Place in Observation" in the medical chart.
If you are unsure, try observation first. It is always possible to
admit the patient if necessary.
Payment for observation is currently bundled into the Medicare
prospective payment for outpatient services with which
observation is associated. Physicians are reimbursed through
the Medicare fee schedule. However, Medical Assistance
does not recognize observation status. The patient is viewed
as an outpatient and the procedure is billed.
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If you have a question related to observation status, please
contact Susan Lawrence, Administrator of Case Management,
at (610) 402-1760.

The Lowering of Vascular
Atherosclerotic Risk (LOVAR) Study:
Is a pound of prevention worth a ton of
cure?
LOVAR is an outcomes-based research initiative designed to
assess the cost-effectiveness of cardiovascular,
cerebrovascular and peripheral vascular disease case
management of patients. It is designed to work with
community physician offices to enhance prevention strategies
and promote durable lifestyle changes in patients at risk for
vascular ischemic events.
The study population consists of Lehigh Valley Hospital (LVH)
patients age 39 to 79 who have documented symptomatic
vascular disease (within the last six months) and have at
least two modifiable risk factors such as diabetes,
hypertension, obesity, high fat diet, smoking, sedentary living,
hyperlipidemia, or exhibit a high degree of depression, hostility,
and stress. The design of the study is a prospective controlled
cohort consisting of 250 controls who will receive community
standard prevention services recommended by their
physicians and 250 cases who will receive the 12-week
comprehensive risk factor reduction program and intensive
coordinated case management services. The goal is to reach
at least 500 patients in the study. To date, 450 patients have
been enrolled in the study.
Patients are followed for at least three years from the date they
enter the study. Examination procedures and medical tests
performed are within the realm of standard treatment for
vascular disease. Participants are encouraged to see their
own physician for regular check-ups and take medications
prescribed by those physicians while in the study.
At least 50 more patients are needed for the study. Physicians
with patients exhibiting the above criteria are encouraged to
enter them into the study. For more information about the
study or to refer a patient, please contact John E. Castaldo,
MD, Principal Investigator, at (610) 402-8420, or Jane M.
Nester, MPH, MEd, Co-Principal Investigator, at (610) 4024088.
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Congratulations!
Gary S. Greenberg, DPM, Division of Orthopedic Surgery,
Section of Podiatry, has been elected Chairman of the Council
of Teaching Hospitals of the American Association of Colleges
in Podiatric Medicine. Dr. Greenberg assumed this position on
July 1. He has been on the Board of Directors of that
organization for four years and has served as Vice Chairman
for the past year.
Herbert L. Hyman, MD, Division of Gastroenterology, has
been appointed Chairman of the Advisory Board of the Chronic
Fatigue Syndrome Research Center, New Jersey Medical
School, Newark, N.J.
Douglas F. Turtzo, MD, Division of Pulmonary, was recently
elected to Fellowship in the American College of Physicians-American Society of Internal Medicine.

Papers, Publications and Presentations
Kelly M. Freed, MD, Division of Diagnostic Radiology, coauthored a paper -- "Breakthrough contrast reactions to lowosmolar contrast media after steroid premedication" --which
was published in the June issue of the American Journal of
Roentgenology. This article reviewed patients who
experienced an adverse reaction to non-ionic contrast
following corticosteroid premedication. Typically, the
breakthrough reaction was of similar severity to the patient's
initial reaction, but was more severe, even life-threatening, in a
minority of patients. In these patients, alternative examinations
such as contrast-enhanced MRI, US, or non-contrast CT
should be performed.
Peter A. Keblish, Jr., MD, Division of Orthopedic Surgery,
was an invited guest speaker at a course - "Current
Controversies in Total Knee Arthroplasty"- held at Lennox Hill
Hospital in New York City. Under the direction of well-known
total joint specialist, Dr. Chitranjan Ranawat, Director of
Orthopaedics at Lennox Hill Hospital, the course emphasis
was on newer concepts of mobile bearing total knee
arthroplasty. Dr. Keblish presented topics related to surgical
approaches, patella management, and wear issues in total
joint replacement. He also participated in a panel of experts
on case report evaluation.
Lester Rosen, MD, Division of Colon and Rectal Surgery, was
the senior author of a paper titled, "Readmissions after
Colorectal Surgery Cannot be Predicted," which was published
in the July 2001 edition of Diseases of the Colon and
Rectum. John J. Stasik, MD, Robert D. Riether, MD, and
lndru T. Khubchandani, MD, all in the Division of Colon and
Rectal Surgery, are among the co-authors.
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The methodology consisted of 249 patients who were operated
on from July 1, 1996 to March 30, 1998. All patients who had
an unplanned related readmission within 90 days of discharge
from the hospital were evaluated. The incidence of unplanned
related readmissions after 90 days was 9%, and these
readmissions could not be predicted from the post-operative
course. As 82% of the unplanned readmissions occurred
within 30 days, this timeframe was deemed more suitable for
computerized analysis. The mean interval between discharge
from the hospital and readmission was 19 days, and the mean
duration of hospital stay during the admission was eight days.
The most common cause of readmission was small bowel
obstruction. Nine of these patients required reoperation.
Additionally, Dr. Rosen was one of the panel members who
participated in the development and review of the American
Medical Association Quality Care Alert on "Colorectal Cancer
Screening and Surveillance." Dr. Rosen represented the
American Society of Colon and Rectal Surgeons. The Quality
Care Alert provides a synthesis of the most recent evidence
and/or recommendations for colorectal cancer screening. The
recommendations relate to asymptomatic individuals as well as
to individuals who are at high risk for colorectal cancer. One of
the newer considerations is that direct colonoscopy screening
of average risk patients every 10 years is an option and is
covered by Medicare beginning July 1, 2001.
For additional information, contact the American Cancer
Society at {404) 320-3333 or visit the website: www.amaassn.org/ama/pub/article/1616-5075.html

MBA Program
DeSales University is sponsoring an Open
House/Information Session on their MBA
Program for Physicians and MSN's.
Classes are held at Lehigh Valley Hospital, .
Cedar Crest & 1-78. For more information,
you .are invited to attend the open house on
Thursday, August:9, at 5 p.m., in Classroom
3 at Cedar Crest & 1~78.
For more information regarding the MBA
Program, please contact Debra
Hockenberry at DeSales University at (610)

282-1100 Ext. 1451.,

Medical Staff Progress Notes

-C'

August, 2001 1

" Who's New
The Who's New section of Medical Staff Progress Notes
contains an update of new appointments, address changes,
resignations, etc. Please remember to update your directory
and roloclexes with this information.

Medical Staff
Address Changes

Jeffrey B. Alpern, DO
P.O. Box 5344
Bethlehem, PA 18015
(610) 758-9432
Fax: (610) 758-9433
Jon E. Brndjar, DO
111 E. Harrison Street
Suite 3
Emmaus, PA 18049-2916
(610) 965-1900
Fax: (610) 965-2900
Debra E. Cressman, MD
Thomas E. Yablonski, MD
215 N. Best Avenue
Walnutport, PA 18088-1204
(61 0) 760-7044
Fax: (610) 760-8587
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Practice Disassociation
Nancy A. Mao, MD
(No longer associated with Drs. Bub and Young Family
Medical Center)
Please forward all correspondence to:
1251 S. Cedar Crest Blvd.
Suite 305-D
Allentown, PA 18103-6205

Practice Name Change
From Harwick, Papola and DeDic Associates
To Harwick and DeDio Associates

Pager Number Change
Barry J. Hennessey, DO
(610) 402-5100 8172

Page 10

Medical Liability Matters
(This information is being provided to you by Robert X. Murphy, Jr., MD, OMSS Representative)

First Two Reform Bills Pass Senate Unanimously
CAT Fund Privatization: With the ink not yet dry on tobacco settlement and budget measures,
legislators in June dug into medical liability and CAT Fund reform initiatives. Amid a flurry of eleventhhour activity on June 19th, the Senate passed SB 556, the Medical Society/Hospital & Healthsystem
Association of Pennsylvania (HAP) proposal to privatize the CAT Fund. The only amendment was a
non-controversial one to aid CAT Fund employees who would stand to lose their jobs with privatization.
Swift passage of SB 556 was facilitated by the Society's continuous meetings and negotiations with
Representative Nick Micozzie (R-Delaware), chair of the House Insurance Committee, and with
Senator Edwin G. Hall (R-Montgomery), key sponsor of the bill. The bill has been referred to the House
Insurance Committee. As detailed in the Joint Medical Society/HAP statement, SB 556 would phase
down the Fund within six years by gradual increases in the primary limits and corresponding decreases
in CAT Fund limits. Transfer of responsibility to the private sector would be financed through a bond
with an annual assessment on health care providers to pay principal and interest costs.
In the House, Representatives Micozzie and Tony DeLuca (D-AIIegheny) this month introduced HB
1802, a mirror of SB 556. Hearings are expected this summer to resolve differences that remain with
the academic health centers. Either bill could carry the Society's CAT Fund privatization proposals
forward.
Frivolous Lawsuit Abuse: Close on the heels of the CAT Fund privatization measure, a State Societysupported bill to curb frivolous lawsuits, Senate Bill406, passed in the Senate 47-0. Following its
unanimous passage, Senator Robert J. Thompson (R-Chester) declared SB 406 the "first step in
medical liability reform." Thompson and Senator James Gerlach (R-Chester) crafted the bill, which
would create a new cause of action for the filing of a frivolous lawsuit, and would allow those subject to
such a suit to immediately seek damages from the frivolous litigant while the frivolous suit is pending.
"Current state law requires that you win your suit before you can file a separate suit claiming
frivolousness," Thompson said. "This is a time-consuming and costly process .... If enacted, this
measure will be a deterrent to those people who would file unwarranted suits that clog our legal system
and are costly to everyone." Senator Gerlach noted in a statement, "Along with the Senate's recent
passing of the medical CAT Fund restructuring, this is another positive step to addressing the medical
malpractice crisis and the burden frivolous lawsuits are placing on the legal system."
Remember: These bills are only the beginning! The Society is working hard over the summer on a
series of tort reform measures to be moved forward in the fall. Each measure will be part of the
Society's overall strategy to design a complete medical liability reform package for Pennsylvania.
How Can You Help?
Physician grassroots support is vital over the summer to continue the momentum of medical liability
reform into the fall session.
·
Both bills-58 406 and SB 556-were passed unanimously by the Senate. These legislators have voted
on your behalf-the physician community-to advance proposals to begin medical liability reform in
Pennsylvania. Let's thank them for their work and their support.
Contact your state senator to thank him or her for voting for the CAT Fund reform bill, SB 556, and the
frivolous lawsuit bill, SB 406. For information on how to contact your legislator, go to
www.pamedsoc.org <http://www.pamedsoc.org/> and click on "advocacy," or call the Liability Reform
Action Center at 1-800-566-TORT (8678).
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NEWS FROM THE LffiRARY.
OVID Instruction.
For personal instruction in the use of'OVID~s MEDLINE
and its other databases, contact Barb Jobst at'610-4028408.

New Library Publications

cc & 1-78
"COLOR ATLAS OF BURN CARE: A COMPANION TO
TOTAL BURN CARE" Author: D. Herndon
"DIABETIC NEUROPATHY."
Author: P. Dyck

2nd

CBT programs replace the instructor-led classes previously
held at Lehigh Valley Hospital. A proctor will be in the room
with the learner while he/she takes the CBT, but the learner
will control the pace and objectives of the learning.

Computer Based Training takes place in Suite 401 of the John
& Dorothy Morgan Cancer Center (the computer training
room) and in the Muhlenberg Hospital Center computer
training room (off the front lobby). The schedule of
upcoming dates is as follows:

CBT sessions for JDMCC, suite 401 are as follows:

edition

17 and Chew Streets
"DENTISTRY FOR THE CHILD AND ADOLESCENT." 1h
edition Author: R. McDonald
"RAPID INTERPRETATION OF EKG's: AN INTERACTIVE
COURSE." 6th edition Author: D. Dubin

August 7, 8 am - Noon
September 18, Noon- 4pm
October 9, Sam- Noon
November 13, Noon - 4pm
December 18, Noon- 4pm
Sessions at MHC, I.S. Training room are as follows:
July 17, Noon-4pm
September 11, Noon- 4pm
November 20, Noon - 4pm

Muhlenberg
"SPORTS INJURY MANAGEMENT." 2nd edition
Author: M. Anderson
"GROSSMAN's CARDIAC CATHETERIZATION.
ANGIOGRAPHY. AND INTERVENTION." 6th edition
Author: D. Bairn.

Computer-Based Training (CBT):
Computer Based Training (CBT) programs are available for
L VHHN staff. Topics covered by the CBT programs include:
Power-Point 4.0
Access 2.0
Windows NT 4
Word 97
Excel 97
Access 97
Lotus 1-2-3 Millennium
PowerPoint 97
WordPerfect 8
E-mail GUI
PHAMIS LastWord Inquiry Only commands

1

Twelve slots are available for each session.
To register, please contact Suzanne Rice via e-mail or at 610402-2475 with the following:
date of session
second date choice
department
phone number
You will receive an e-mail confirming your choice within two
business days. If you have any questions, please contact Craig
Koller at 610-402-2413 or through e-mail.
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Nursing Programs
CRITICAL CARE COURSE/INTERNSHIP
Program Coordinator: Edith Gray, MSN, Ed. Specialist
Phone: 610-402-2348 I Pager 610-830-6019
CEDS 610-402-2277

************************************************
DAY 1 - CARDIOVASCULAR
Tuesday, August 7, 2001, SON Aud, 17th/Chew
07 45
Registration
800
Intro to Course Objectives & History of Critical Care
Nursing and AACN
Applied Cardiovascular Physiology Cardiovascular
Pathophysiology & Caring for Patients with:
-Hypertensive Crisis
- Heart Failure and Pulmonary Edema
- Acute Coronary Syndromes
--Angina
-- MI
-- Vavular
-- Cardiomyopathy
Cardiovascular Pathophysiology
Interventional Cardiology
Cardiac Rehabilitation & Patient Teaching
Panel Discussion

**************************************************
DAY 2 - CARDIOVASCULAR
Wednesday, August 8, 2001, SONRoom#900, 17th/Chew
745
Registration
800
Cardiac Pacemakers: Temporary & Permanent
12LeadECG
Caring for Patients Requiring Cardiovascular
Interventions
- Cardioversion!Defibrillation
EPS/Ablation!ICDs

***************************************************
DAY 3- PULMONARY/MECHANICAL VENTILATION
Thursday, August 16,2001, JDMCC Classroom #8 3rd Floor
0745
Registration
0800
Pulmonary Assessment
Acid Base Balance
Concepts of Oxygenation
Oxygen Therapy and Airway Management
Principles of Mechanical Ventilation
Advanced Mechanical Ventilation Concepts

***************************************************
DAY 4- PULMONARY/MECHANICAL VENTILATION
Friday, August 17,2001, SON Aud, 17th/Chew
07 45
Registration
0800
Weaning of Ventilatory Dependent Patient Carino0 for
Patients With:
.
-ARDS
- Respiratory Failure
-COPD

2

- Status Asthmatics
- Pulmonary Embolism
Care of the Thorocotomy Patient, Chest Tube
Management and Heimlich Valve
Care of the Patient Rec~iving Neuromuscular
Blockade and Use ofPNS
Care of the Immunologically Compromised Patient

**************************************************
DAY 5 -HEMODYNAMIC MONITORING
Monday, August 20, 2001, EMI, 2166 S. 12th St.
07 45
Registration
0800
Caring for the Cardiovascular Patient Requiring
Antiarrhythmics and Vasoactive Medications
Hemodynamic Monitoring I Use of Pressure Monitor
Lines
-RA,RV,PA,PAWP

-RAP, PAP
- CO/CIISVR
-Invasive BPIA-Lines
-CVP
Workshops/Case Studies with Simulator
Pressure Monitor Lines
Medications Calculations

*************************************************
DAY 6 -NEUROSCIENCES
Thursday, September 6, 2001, SON, Aud, 17th/Chew
07 45
Registration
0800
Neurological Anatomy and Physiology
Neurological Assessment
Spinal Cord Anatomy and Physiology and
Spinal Cord Assessment
CSF Circulation and Principles of ICP Monitoring
Central Nervous System Infections
Space Occupying Legions and
Spinal Cord Tumors
Nursing Management of the Patient with Seizures
Neurological Hemorrhages
Caring for Patients with Strokes

**************************************************
DAY 7 - GASTROINTESTINAL
Friday, September 7, 2001, SON, Aud, 17th/Chew
07 45
Registration
0800
Nutritional Management in Critical Care Patients
Alterations in GI Tract -- Anatomy and Physiology,
Assessment
Caring for Patients with:
- Hepatic Failure/Cirrhosis
- Acute Pancreatis
- Gastrointestinal Bleeding/Hemorrhages
- Coagulopathies
- Multiple Organ Dysfunction Syndrome
- Multiple System Failure

****************************************************
DAY 8 -RENAL/ENDOCRINE
Monday, September 24, 2001, SON Room #900, 17th/Chew
07 45
Registration
0800
Caring for Patients with Fluid and Electrolytes I
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Imbalances
Renal Assessment/Renal Failure
Organ and Tissue Donation
Renal Transplant
Diabetes Insipidus/SIADH
Caring for Patients in a Metabolic Crisis of
Diabetes Metlitus - DKA/HHNS

**************************************************
DAY 9 -NEEDS OF MULTI-SYSTEM CRITICAL CARE
PATIENT
Friday, September 28,2001, SON Aud, 17th/Chew
Registration
0745
Shock States
0800
- Cardiogenic Shock
- Distributive Shock
- Hypovolemic Shock
- Neurogenic Shock
Caring for the Patient with Heart Failure and
Pulmonary Edema
Care of the Post-Anesthesia Patient in Critical Care
Epidural Analgesia/Neuromuscular Blockade
Pulmonary Positioning
Caring for the Patient with Peripheral Vascular
Disease
- Carotid Stenosis
-Aneurysms
--Thoracic
-- Abdominal Aortic Aneurysms
Assessment and Nursing Management of the Patient
with Peripheral Vascular Disease
Degenerative Disease of the Nervous System
-Multiple Sclerosis- Gullian Barre' Syndrome
Amyotrophic Lateral Sclerosis - Myasthenia
Gravis
Drug Overdose

PRECEPTOR PROGRAM
Educational program for RN's who will be assigned
responsibility to orient new staff to their clinical unit.
Date
Wed., 8/15/01
Mon., 12/10/01

Time
0745-1630
0745-1630

Location
Classroom #8-JDMCC
Classroom #8-JDMCC

REGISTRATION:

LVHHNStaff
--Please access the Bulletin Board entitled Forms_Nursing.
-- Select the Cont. Education Registration Form.
-- Right click on the form and choose "Use Form".
--Complete all areas (refer to "How To Register" for more
help on using forms).
-- Indicate which day you will be attending.
--Use the comments section to provide us with any additional
information that may be useful.
-- We will be unable to process incomplete registrations.

PennCARE Affiliates and Staff without E-Mail Access
--Please either call (610-402-2277) or fax (610-402-2203) the
·following information: name, hospital affiliation, position,
mailing address, social security#, daytime phone#, and day
attending. We will be unable to process incomplete
registrations.

If you have any questions, please call the Center for Education
at 610-402-2277.

**************************************************
DAY 10- HOLISTIC CRITICAL CARE ISSUES
Monday, October 1, 2001, SON Aud 17th/Chew
0745
Registration
0800
Ethics in Critical Care
Risk Management in Critical Care
Sleep Deprivation
Psycosocial Considerations in Critical Care
Care of the Perinatal Patient in Critical Care
Geriatric Issues in Critical Care
Conscious Sedation

*************************************************
CARDIOVASCULAR SURGERY MODULE
Monday, September 17,2001, SON Aud, 17th/Chew

***************************************************
FEE: $90.00 PER DAY
Fee is waived for employees of L VHN and PennCARE

***************************************************

3

Any questions, concerns or comments on articles from CEDS, please contact
Bonnie Schoeneberger 610-402-2584

August
Sun

Mon

Tue

Wed

Thu

Fri

Sat

1

2

3

4

12 noon Combined TBJDMCC-CRI

5

I

6

12 noon Colon/Rectal
TB-JDMCC-CRI

12

13

7
7am Family Practice
GR-JDMCC-CRlAIB
Sam Pediatric GR-CCAud

14

8
12 noon - Grand
Rounds - Chest
Auscultation Workshop
12 noon-Pulmo TBJDMCC-CRl

15

19

20
12 noon Colon/Rectal
TB-JDMCC-CRI

26

27

21

22

28
Sam Pediatric GR-CCAud
12 noon-Urology TBJDMCC-CRI

12 noon-G. I. TBJDMCC-CRI

29

17

12 noon Combined TBJDMCC-CRI

18

7am OBGYN GR-CCCLI
12 noon-Breast TBJDMCC-CRI

23
30

11

7am OBGYN GR-CCCLI
12 noon-Breast TBJDMCC-CRl

16
12 noon-ENT TBJDMCC-CRI

Sam Pediatric GR-CCAud

10

9

12 noon Combined TBJDMCC-CRl

Sam Pediatric GR-CCAud

7pm-GYN TBJDMCC-CRJ
12 noon-Breast TBJDMCC-CRI

24

25

7am OBGYN GR-CCCLl
12 noon-Breast TBJDMCC-CRl

I

31

7am OBGYN GR-CCCLl
12 noon-Breast
TB-JDMCC-CRI

2001
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THERAPEUTICS AT A GLANCE
The following actions were taken at the June 2001 Therapeutics Committee Meeting -Joseph Ottinger R.Ph. MS MBA J · B
b R Ph
Jenny Boucher, Pharm.D.
•
•
•
• anme ama y, . .,

Drug Formulary Issues- Dalteparin,
Ziprasidone, Bisoprolol
LMWH (Low Molecular Weight
Heparin) OVERVIEW:
The Low Molecular Weight Heparins (LMWH)
currently available in the U.S. are all
depolymerized porcine mucosal heparin
preparations. They are prepared by chemical or
enzymatic cleavage of the animal source
heparinoid molecule. These products exhibit
differences in both their structures and functional
properties and are not considered interchangeable
nor have their been any studies comparing these
agents head-to-head. In addition to effects on AT
ill (antithrombin ill), factors IIa, Xa, and IXa,
additional mechanisms of action may mitigate a
current comparison of anticoagulative properties.
Other actions identified include the release of
tissue factor pathway inhibitor (TFPI) ;
interactions with heparin cofactor IT; inhibition of
leukocyte procoagulant actions; promotion of
fibrinolysis; and alteration of protein/ vascular
endothelium binding sites.
The three trials most pertinent trails involving
LMWH in the treatment of unstable/ NSTEMI are
the FRIC, ESSENCE and TIMI llb trials. All
ttlese trials compared a LMWH vs unfractionated
hepariii (UFH). Dalteparin (FRIC) and
enoxaparin (ESSENCE; TI.MI llb) were the
agents involved. There are no direct comparisons
between these two agents. So comparative
analysis must proceed based on a knowledge of the
trial methodology, patient populations, definition
of outcomes, and the clinical significance of those
outcomes The ESSENCE trial utilized an
empirical dosage protocol for UFH that was

supposed to achieve a targeted therapeutic level
(PTT) within 24 hours. Only half the patients
enrolled in this arm were in the therapeutic range
at any point in the study .. In addition, the lack of
correspondence of PTT and UFH concentrations
has been fairly well demonstrated in a number of
papers and has been the primary reason for a
'push' toward reporting heparin levels. The
ESSENCE trial utilized 176 different centers each
using that institutuion's reagent standardization
procedure. As with pre-INR standardization for
warfarin therapy, using aPTT values to drive UFH
dosing may not correlate with therapeutic
objectives.
Patients enrolled in both the ESSENCE and TIMI
llB trials generally were sicker with more patients
at baseline with NSTEMI, previous MI and more
patients were protected by ASA at time of
enrollment. Additionally, the TIMI llB trial
utilized an IV loading dose of enoxaparin that is
not currently approved prior to using the lmg/kg
SC BID regimen and thus confounds combining
data from the two studies, although a meta analysis
has been published providing us with this insight.
Baseline Characteristics:
FRIC
NQWMI(%)
16

ESSENCE
21

TIM! llB

35

Previous Ml(%) 25

46

32

56

62

84

ASA users (%)

The FRIC trial was utilized to gain FDA approval
for the unstable angina treatment indication, but
none of its endpoints were statistically significant
vs. its UFH arm. One mitigating issue identified
with the trial design was the provision to enroll
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patients up to 72 hours after the initial patient
presentation (vs. 24 hours for the enoxaparin
trials). Clearly, the perceived advantage of
LMWH vs. UFH would be their superior kinetic
profile resulting in a faster time to therapeutic
anticoagulation. As mentioned previously, the
study population was not at as great a risk as the
enoxaparin populations. Therefore, the relative
risk reduction would not be expected to be as
dramatic.
The elaboration of different primary clinical
endpoints also confounds a meaningful comparison
of the various trials. The definition of recurrent
angina is particularly problematic in assessing the
outcome points. The FRIC trial defmed it simply
as chest pain requiring IV nitroglycerin, while
both ESSENCE and TIMI llB used a more
detailed assessment parameter of rest angina of at
least 5 minutes duration, associated with either
new ST segment shift or T wave inversion; angina
that prompted revascularization; or post discharge
angina that prompted re-hospitalization. This is
particular interest in that the statistically significant
TEP (triple end-point) was driven primarily by the
recurrent angina endpoint. Neither of the Death
nor MI endpoints were statistically significant at
any point in the analysis.
Finally, the theoretical benefits of providing
therapeutic anticoagulant effects earlier in
treatment (i.e., thrombolytic tx) do appear to favor
utilization of agents that provide an immediate
onset of action that can be consistently duplicated
without intensive monitoring, thus favoring use of
LMWH. However, the perceived advantage of
not having to monitor patients on LMWH can
create a false sense of security related to the nature
and extent of bleeding. Clinical trials for the
LMWH have excluded patients with compromised
renal function; while limited data is available for
treatment of obese/extremely lean patients .
Expert recommendations for these patient groups
range from empiric dosing without monitoring for
limited duration of therapy to using recommended

dosing with follow-up laboratory surveillance
utilizing anti-factor Xa heparin activity levels or a
combination of both.

Fragmin (dalteparin)

is indicated for the
adjunctive treatment of unstable angina/NSTEMI.
Its other indications for prophylaxis of DVT/PE
will not be addressed here.
CLINICAL PHARMACOLOGY :Dalteparin is a
low molecular weight heparin analog with a
molecular weight of 4,000 to 6,000 daltons.
While dalteparin has been shown to inhibit both
factor Xa and factor Ila (thrombin), the
antithrombotic effect of dalteparin is characterized
by a higher ratio of antifactor Xa to antifactor Ila
activity.
ADVERSE REACTIONS: Adverse reactions
reported with dalteparin therapy include bleeding,
wound hematoma, injection site hematoma,
thrombocytopenia, pain at injection site, allergic
reactions (eg, pruritus, rash, fever, injection site
reaction, bulleous eruption), anaphylactoid reactions
and skin necrosis.
Hematologic complications that occur with
dalteparin appear to be dose dependent. Patients
with severe uncontrolled hypertension, bacterial
endocarditis, congenital or acquired bleeding
disorders, active ulceration and angiodysplastic
gastrointestinal disease, hemorrhagic stroke, or
shortly after brain, spinal or ophthalmological
surgery might be at increased risk of hemorrhage.
Dalteparin therapy is contraindicated in patients
with known hypersensitivity reactions to heparin,
pork products or dalteparin. The drug is also
contraindicated in patients with active major
bleeding or thrombocytopenia associated with
positive in vitro tests for antiplatelet antibody in the
presence of dalteparin.
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RECOMMENDED MONITORING: Because
dalteparin has a higher ratio of factor Xa:factor Ila
activity, it does not produce marked increases in
aPTT and thus, this parameter is not useful. For the
purpose of clinical investigation, many studies have
quantified plasma antifactor Xa activity for efficacy
and safety. In addition, complete blood counts,
platelet counts and stool occult blood tests should
be monitored periodically during the course of
therapy.
DOSING: Recommended dosing ofdalteparin in
the treatment of unstable angina/NSTEMI is 120
units/kg every 12 hours via subcutaneous injection.
Patients weighing more than 81 kg are 'capped' to a
dose of 10,000 units every 12 hours.
This product was approved to the Formulary. An
autosubstitution was also approved related to initial
enoxaparin orders for the adjunctive treatment of
unstable angina/ NSTEMI and anticoagulation
'bridges' for atrial fibrillation and/or valve
replacement. A copy of this notice appears below:
Dear Doctor:
The Therapeutics Committee has approved an
autosubstitution for all orders received using
enoxaparin 'treatment' regimens in patients with
unstable angina, non ST elevated myocardial
infarction, or for 'anticoagulation 'bridges' in patients
with atrial fibrillation or prosthetic valves. These
orders will be automatically substituted by pharmacy
to dalteparinl20 units/kg q12h (up to 82 kg) or
10,000 units (Patients weighing>82 kg) q12h via
subcutaneous injection.
ALL doses will be rounded to the closest 100 unit
dose. Patients with estimated creatinine clearance
of less than 30ml/min (Cockroft-Gault calculation) will
not be changed.
However, use of low molecular weight beparins in
patients with compromised renal function in
treatment regimens has not been studied. All
published data to date have EXCLUDED this patient
population, therefore no dosing guidelines are
available to direct therapy in these individuals. There
are data to suggest that the excretion of LMWHs
will be reduced in moderate renal failure, leading to

drug accumulation and a higher risk of bleeding. As
LMWH's effects on anticoagulation cannot be
monitored via "standard" laboratory measures, it
would seem prudent to consider using another
agent for anticoagulation. Therapeutic unfractionated
heparin is generally considered equally effective and
safe in all indications where treatment regimens of
low molecular weight heparins are currently
approved. If you have any questions, please, call 8884
the Pharmacy department.
Thank you for your cooperation.

Geodon (Ziprasidone) is indicated for the
treatment of schizophrenia. When selecting
between antipsychotics available for the treatment
of schizophrenia, the prescriber should consider
ziprasidone's greater capacity to prolong the
QT/QTc interval compared to several other agents.
Prolongation of the QTc interval by other
medications has been associated with torsades de
pointes-type arrhythmia and sudden death. It is not
yet known if ziprasidone will cause torsades de
pointes or increase the rate of sudden death;
however, depending on patient circumstances one
could conclude that another drug should be tried
first.
CLINICAL PHARMACOLOGY: Ziprasidone is
an atypical antipsychotic agent of the
benzisothiazole class, which structurally resembles
risperidone (a benzisoxazole). Ziprasidone is a
combined serotonin and dopamine receptor
antagonist. It also has activity at the serotonin and
dopamine transport or re-uptake sites; however, the
importance of this activity is unknown.
PHARMACOKINETICS: Peak ziprasidone
levels are reached within 3 to 8 hours following oral
administration. Oral bioavailability is 59%.
Administration with or immediately after a high-fat
meal increased the mean AUC by 45% to 69% and
the peak concentration by 40% to 67% Ziprasidone
is extensively plasma protein bound (>99%),
primarily to albumin and a 1-acid glycoprotein.
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Ziprasidone is extensively metabolized by four
metabolic pathways. CYP3A4 is responsible for the
primary oxidative metabolites, including the major
metabolites ziprasidone sulfoxide and ziprasidone
sulfone. The mean half~life is 7 hours (3.2 to 10
hours). Less than 5% of the dose is excreted
unchanged in the urine or feces. Overall, 20% of
the dose is excreted in the urine and approximately
66% is excreted in the feces. In patients with mild,
moderate, or severe renal impairment, the
pharmacokinetics of ziprasidone did not differ from
those observed in healthy controls. Hemodialysis
does not affect the pharmacokinetics of ziprasidone.
ADVERSE REACTIONS: Side effects in the
clinical trials have included dyspepsia, constipation,
nausea, abdominal pain, dry mouth, sedation,
headache, postural hypotension, dizziness,
insomnia, akathisia, and rash. Postural hypotension,
dizziness, and somnolence were more likely to
occur on the first day of dosing. Asthenia, postural
hypotension, anorexia, dry mouth, increased
salivation, arthralgia, anxiety, dizziness, dystonia,
hypertonia, somnolence, tremor, rhinitis, rash, and
abnormal vision appeared to be dose related.
Extrapyramidal effects occurred in 5% of patients.
Elevated eosinophil levels and elevated
transaminase levels occurred in a small number of
ziprasidone-treated patients.
DRUG INTERACTIONS: Ziprasidone should not
be administered with any medication that prolongs
the QT interval. Caution is recommended when
ziprasidone is administered in combination with
other centrally acting agents due to the central
nervous system effects of ziprasidone. Ziprasidone
may enhance the effects of some antihypertensive
agents due to its potential for inducing orthostatic
hypotension. Ziprasidone may antagonize the
effects of levodopa and dopamine agonists.
CYP3A4 inhibitors may decrease ziprasidone
metabolism.

DOSING: Ziprasidone therapy should be initiated
at a dose of 20 mg twice daily with food. The dose
may subsequently be increased based on response
up to 80 mg twice daily. Dosage adjustments
should occur at intervals of not less than 2 days.
Patients should be observed for improvement for
several weeks before upward dosage adjustment to
ensure use of the lowest effective dose.
To summarize: Ziprasidone is an effective
antipsychotic with efficacy comparable to
haloperidol. It has not been associated with weight
gain, making it unique within this class of
pharmacologic agents. Ziprasidone has been
associated with increases in QTc interval, which
will restrict its use in some populations.. Use of
other agents that also prolong the QT interval or
interfere with the metabolism of ziprasadone
warrants close monitoring. It is available in 20 mg,
40 mg, 60 mg, and 80 mg capsules; all strengths
have a drug acquisition cost of $3.1 7 each. This
strategy places this agent firmly in the
'middleground' ,as regards drug cost Vs. other
atypical antipsychotic agents and at higher doses
may provide some cost advantages.

Zebeta (Bisoprolol fumarate)

is a beta !selective (cardioselective) adrenoreceptor blocking
agent without significant membrane stabilizing
activity or intrinsic sympathomimetic activity in its
therapeutic dosage range. Cardioselectivity is not
absolute, however, and at higher doses ( 20 mg)
bisoprolol' fumarate also inhibits beta 2adrenoreceptors, chiefly located in the bronchial and
vascular musculature.
Bisoprolol is at least as effective in controlling heart
rate and blood pressure as other marketed beta
blockers. It also has been shown to have some
beneficial effects in patients with CHF (carvedilol
and metoprolol also have studies suggesting benefit
in patients with varying degrees of CHF). There are
a significant number of patients admitted to L VH,
whose BP is already 'controlled' on this agent or
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this agent in combination with HCTZ (Ziac). Its
acquisition cost is comparable to other agents in this
class (about$ 0.20 per day). Therefore, it was
recommended by the Therapeutics committee to
approve the addition of this selective. beta 1
receptor blocker to the current Formulary. It was
also recommended that timolol be removed from the
formulary, as this product provides no advantages
over other available beta blockers arid has no
significant level of usage by prescribers at LVH.

ADR Reports:
ADR reports have stayed consistent with 71 reports
in the first quarter of2000.
Pharmacists and nurses completed about 95% of the
reports. There has been a large increase in the
number of reports generated in the outpatient area
due to newer monoclonal agents. Below is a
synopsis of the first quarter.
111 Quarter Data
Table I :

Phannacist
Nurse
Physician
RT
Student
TOTAL

Table 2 :

Reports
43
25
1
1

%Reoorts
60.6
35.2
1.4
1.4
1.4
100

_!
71

Adverse Reactions by Drug Category

Drug Category
Antibiotics
Anticoagulants
Oncology

#Reoorts

20
12
10
Psych/Neurologic Agents . 10
Narcotic Analgesics
6
Contrast Dye
4
Dopamine
2
Other
1
TOTAL
71

Table 3: Probability of Drug -Related Reactions

Probability
Doubtful
Possible

o/oReports
28.1
16.9
14.1
14.1
8.5
4.2
2.8
11.3
100

#Reports

o/oReports

1
20
48

1.4
28.2
67.6
2.8

Probable
Highly Probable

.l

TOTAL

71

100

Table 4: Advene Reaction Severity
Classification
#Reports
%Reports
Mild
29
40.8
Moderate
36
50.7
Severe
.§.
11
TOTAL
71
100

ptlhijuneOl

Adverse Reactions By Reporter

Reporter

Top 5 Agents by# of Reports
Cefazolin
6
Reopro(w/ heparin)
5
Vancomycin
5
Rituxan
4
Remicade,morphine,
3
Contrast,clindamycin
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